Traina M, Rotolo A, Trapani R, Messina L, Candela B, Mercurio G, Raineri A
Cattedra di Fisiopatologia Cardiovasculare, Università degli Studi, Palermo.
Cardiologia. 1990 Jan;35(1):55-60.
Several studies have demonstrated that enalapril causes a clinical and hemodynamic improvement in patients with congestive heart failure. Nevertheless, the drug capability of influencing left ventricular systolic and diastolic indexes has not been evaluated. In 12 patients with severe congestive heart failure (NYHA class III-IV), treated with digitalis and diuretics, we performed a baseline evaluation through a right heart catheterization, echocardiography and radionuclide ventriculography. The effects on left ventricular systolic and diastolic function indexes after the administration of enalapril 5 mg by oral route have been evaluated. After 3 months of chronic therapy with enalapril 5 mg twice daily, we performed a further evaluation through echocardiography and radionuclide ventriculography. At the acute test we observed a significant improvement of left ventricular ejection fraction (EF), left ventricular stroke index (LVSI), and peak of filling rate (PFR), with a significant reduction of pulmonary wedge pressure (PWP) and peripheral vascular resistance (PVR). After 3 months of chronic therapy EF was significantly increased with respect to baseline values (37 +/- 6.9% vs 28.7 +/- 7.9%, p less than 0.05) and showed a further increase after the drug administration (from 37 +/- 6.9% to 48 +/- 5.4%, p less than 0.001). PFR showed a similar behaviour and reached at the follow-up evaluation normal values (from 1.97 +/- 0.7 edv/s to 2.57 +/- 0.6 efv/s, p less than 0.001). Furthermore, the echocardiographic dimensions of the left ventricle decreased significantly with a significant increase of shortening fraction. In conclusion, our study demonstrates that in patients with severe congestive heart failure enalapril improves the left ventricular systolic and diastolic function indexes and this improvement is persistent.
多项研究表明,依那普利可使充血性心力衰竭患者的临床症状和血流动力学状况得到改善。然而,其对左心室收缩和舒张指标的影响尚未得到评估。我们选取了12例重度充血性心力衰竭(纽约心脏协会III-IV级)患者,这些患者正在接受洋地黄和利尿剂治疗,通过右心导管检查、超声心动图和放射性核素心室造影进行了基线评估。评估了口服5毫克依那普利后对左心室收缩和舒张功能指标的影响。在每天两次服用5毫克依那普利进行3个月的长期治疗后,我们通过超声心动图和放射性核素心室造影进行了进一步评估。在急性试验中,我们观察到左心室射血分数(EF)、左心室每搏输出指数(LVSI)和充盈率峰值(PFR)显著改善,肺楔压(PWP)和外周血管阻力(PVR)显著降低。经过3个月的长期治疗,EF相对于基线值显著增加(37±6.9%对28.7±7.9%,p<0.05),并且在给药后进一步增加(从37±6.9%增至48±5.4%,p<0.001)。PFR表现出类似的变化,在随访评估时达到正常值(从1.97±0.7 edv/s增至2.57±0.6 efv/s,p<0.001)。此外,左心室的超声心动图尺寸显著减小,缩短分数显著增加。总之,我们的研究表明,在重度充血性心力衰竭患者中,依那普利可改善左心室收缩和舒张功能指标,且这种改善是持续的。